We leveraged the power of single-cell genomics to characterize the heterogenous cell types and states in the tumor microenvironment (TME). By profiling thousands of single cells from surgical resections of gastric cancer together with paired normal mucosa and peripheral blood mononuclear cells (PBMCs), we determined the deviations in the TME from physiological conditions. Our analysis revealed a cellular reprogramming of the TME compared to normal mucosa in immune and stromal lineages. We detected transcriptional heterogeneity within macrophages and a TME-specific gene expression program in dendritic cells. Cytotoxic T cells in the TME had heterogenous profiles of exhaustion and expression of multiple immune checkpoint and costimulatory molecules. We constructed a receptor-ligand based inter-cellular communications network that was exclusive to tumor tissue. These discoveries provide information at a highly granular cellular resolution enabling advances in cancer biology, biomarker discovery and identification of treatment targets such as for immunotherapy.
INTRODUCTION
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide (1) . The current histopathologic classification scheme designates GCs as either intestinal or diffuse subtype according to the differentiation and cohesiveness of glandular cells and other features of cellular morphology (2). Intestinal GC is preceded by changes in the gastric mucosa called the Correa cascade that progresses through inflammation, metaplasia, dysplasia and adenocarcinoma. Diffuse GCs lack intercellular adhesion and exhibit a diffuse invasive growth pattern. Recent integrated genomic and proteomic analyses including by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) (4,5) have refined the classification of GC and revealed that they fall into several distinct molecular subtypes that include the intestinal and diffuse classification. Regardless of the histopathologic or molecular subtype, GCs are not isolated masses of cancer epithelial cells -rather they have a complex morphology where cancer cells are embedded and/or surrounded by a diverse assortment of different cell types (3). Referred to as the tumor microenvironment (TME), this cellular milieu contains fibroblasts, endothelial, immune and other diverse cell types.
Interactions among the cellular components of the TME and cancer cells enable tumors to proliferate, metastasize and alter the response of the immune system. Increasingly, it is recognized that the cellular features and interactions of the TME components play an important role in GC biology and determine the efficacy of specific treatments such as immunotherapy. There are general mechanisms where gastric tumor cells suppress the local immune cells and dysregulate the patient's immune system (4). Moreover, tumors are stimulated by various growth factors that originate from the cellular compartments within the TME. Thus, the cellular characterization of the TME provides a more sophisticated picture of the context of tumor cell growth within its tissue of origin, characteristics of immune infiltrate and inter-cellular interactions. These are important elements that determine therapeutic response but have not been characterized.
The major objective of this study was to determine the specific cellular and transcriptional features that distinguish the GC TME from normal gastric tissue. We sought to define these differences at the resolution of single cells with single cell RNA-seq (scRNA-seq). We delineated cell-specific features that are otherwise lost when using "bulk" methods in which molecular analytes cannot be attributed to their cell-of-origin. Our study used matched gastric tumor and normal tissue from the same patients. We made comparisons among these paired normal-tumor samples as well as extrapolated the more global cellular TME differences noted among all of the samples. In addition, we had peripheral blood mononuclear cells (PBMCs) for a subset of patients from which we made comparisons with tumor infiltrating immune cells. Our analysis considered both the pathologic category as well as distinguishing features that delineate the molecular subtype.
To identify the cellular and transcriptional features of cells in the gastric TME, we developed an extensive analytical framework ( Figure 1A ) (5) (6) (7) (8) . With single cell resolution, we identified multiple differences between the tumor and normal epithelium and conducted differential gene expression analysis for each cell type in the context of the gastric TME versus the normal stomach. Our results indicated specific cellular programming states based on changes seen in gene expression and extrapolated cellular regulatory networks. Finally, we identified important inter-cellular communication networks specific to the gastric TME compared to the gastric normal tissue. Our study identified cellular and biological features that are specific to the TME, and thus offer insight which may help infer new therapeutic targets.
METHODS

Sample acquisition and tissue processing
All samples were acquired with informed consent under an approved institutional review board protocol from Stanford University. Gastric tumor and metaplasia samples were obtained from surgical resections or endoscopic biopsies. In parallel, we also obtained tissue from matched normal gastric sites that were displaced at least several centimeters from the tumor. The normal gastric tissue was confirmed to lack tumor cells based on histopathology review.
Tissues were collected in plain RPMI immediately after surgical resection and stored on ice.
Following dissection with iris scissors, tissue fragments were subjected to enzymatic and mechanical dissociation using human tumor dissociation kit (Miltentyi Biotec, Germany) with the Gentle MACS Octodissociator (Miltenyi) as per manufacturer's protocol with the '37_h_TDK_3' program. For biopsy specimens, half the volume of media and enzymes were used.
Dissociated cells were incubated with RBC lysis buffer (155 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM EDTA) for 10 minutes followed by neutralization with PBS. All centrifugation steps were carried out at 400g for 3 minutes.
Blood collected in EDTA or sodium heparin was overlaid on 15 ml Ficoll-Paque Plus (GE healthcare, Chicago, IL) contained in a Sepmate 50 ml tube (Stemcell Technologies, Vancouver, Canada), and centrifuged for 10 minutes at 1200g. Interphase containing the PBMCs was decanted into a fresh tube followed by 2 washes with PBS with centrifugation at 400g for 3 minutes. Cells were cryofrozen using 10% DMSO in 90% FBS (Thermofisher Scientific, Waltham, MA) or Cryostor CS10 (StemCell Technologies) (for P6709 samples) in a
Clustering analysis
We used Seurat (v2.3.4) (8) to create data objects from the matrix outputs. We removed cells that expressed fewer than 200 genes, had greater than 20% mitochondrial genes or had number of UMI in an outlier range indicative of potential doublets ( Supplementary Table S1 ).
We excluded genes detected in fewer than three cells. Data was normalized to log scale using the 'NormalizeData' function with a default scale parameter of 10000. Highly variable genes were identified using the 'FindVariableGenes' function with parameters for x.low.cutoff=0.0125,
x.high.cutoff=6 and y.cutoff=0.5. The effects of variation in sequencing depth were regressed out by including 'nUMI' as a parameter in the 'ScaleData' function. These variable genes were used as input for PCA using the 'RunPCA' function. The first 20 principal components (PCs) and a resolution of 0.8 were used for clustering using 'FindClusters'. UMAP was used for twodimensional representation of first 20 PCs with 'RunUMAP'. Differential gene expression for identifying markers of a cluster relative to all other clusters or compared to a specific cluster was determined using the 'FindAllMarkers' or 'FindMarkers' functions respectively. Parameters provided for these functions were: genes detected in at least 25% cells; differential expression threshold of 0.25 log fold change using Wilcoxon rank sum test with p < 0.05 following Bonferroni correction. We compared the marker genes for each cluster to literature-based markers of cell lineages to assign a cell lineage per cluster ( Supplementary Table S2 ).
Individual Seurat data objects were merged iteratively using the 'MergeSeurat' function after filtering doublets identified by DoubletFinder, an R package that enables computational identification of doublets (Supplementary methods). The merged object was processed as described above with library preparation batch and number of UMIs ( Supplementary Table S1) included as parameters for regression in the 'ScaleData' function to regress batch effects and variation in sequencing depth respectively. The 'DoHeatmap', 'FeaturePlot', 'DimPlot', DotPlot', 'VlnPlot' were used for visualization.
For a secondary cluster analysis of each cell lineage from this aggregated dataset, clusters of interest were identified and subset using 'SubsetData' with parameter 'do.clean' set to true.
Detection of variable genes, scaling with UMI regression, PCA, clustering and UMAP were repeated as described above. Following this step, we removed clusters with co-expression of cell lineage markers as multiplets ( Supplementary Table S3 ). Proportions of each cell type relative to the total number of cells in the sample were compared for tumor and normal sites using two proportions z-test and represented as box plots after re-clustering analysis for each lineage. Additional description of methods is available under Supplementary Methods.
RESULTS
Cohort of gastric cancer and intestinal metaplasia
We obtained tissues from surgical resections or endoscopic biopsies from seven patients with GC and one patient with gastrointestinal metaplasia (GIM). These tissue samples represented paired gastric tumor and gastric normal tissue from the same patient derived from the same anatomical region of the stomach. Specifically, four tumors were located at the gastroesophageal junction (GEJ) and four were located in the body and antrum. Also, we analyzed matched peripheral blood mononuclear cells (PBMCs) from two patients. Based on histopathology review, the GC tumors had intestinal, diffuse or mixed features ( Supplementary   Table S4 , Figure 1B, Supplementary Figure 1A) . The majority of samples had immunohistochemistry (IHC) testing for protein expression of MLH1, MSH2, MSH6 and PMS2 which are proteins involved in DNA mismatch repair. We used these IHC results to classify tumors into microsatellite stability (MSS) or microsatellite instability (MSI) molecular subtypes ( Supplementary Table S4 , Supplementary Methods). Histopathology showed that three patients (P5866, P6207, P6342) had active gastritis or intestinal metaplasia in paired nonmalignant tissue.
Single-cell transcriptomic profiles from gastric cancer
With scRNA-seq, we obtained transcriptional profiles of 32,407 single cells from tumors or metaplasia, 18,657 single cells from paired normal tissue and 5,103 PBMCs ( Supplementary   Table S1 ). To determine cell type and gene expression changes, we employed a series of analytical steps for each individual scRNA-seq dataset. This included quality filtering the single cell data (Methods), principal component analysis (PCA) on genes that were variably expressed across cells and graph-based clustering on the first twenty principal components (8, 9) . In addition, we employed uniform manifold approximation and projection (UMAP) to reduce the dimensionality of this data and allow the visualization of cell-type clusters defined by their transcriptional profiles. Differentially expressed (DE) genes were identified by selecting genes expressed in greater than 25% of cells in a cluster and having a log fold change greater than 0.25, using a cut-off of p < 0.05 following Bonferroni correction. We compared the DE genes from each cluster to known marker genes of various cell types ( Supplementary Table S2 ). This information enabled us to link clusters to specific cell types including epithelial cells (expressing PGC, TFF1, MUC5AC, EPCAM, GIF, CHGA), fibroblasts (THY1, DCN, COL4A1, FAP) , endothelial cells (PECAM, ENG, VWF, SELE), immune cells (PTPRC) such as CD4 T (CD3D, CD4, IL7R), cytotoxic T (CD3D, CD8A, CD8B), regulatory T (FOXP3, IL2RA), NK (NKG7, GNLY), B (MS4A1), plasma cells (immunoglobulin genes), mast cells (TPSAB1) and macrophages (CD68, CD14, FCGR3A).
Examination of cells expressing markers of disparate cell types facilitated the computational detection of doublets ( Figure 1C, 1D, Supplementary Methods) .
Data integration for joint cell analysis across all samples
To determine both the similarities and differences among all of the matched samples including GC, metaplasia and normal gastric cells, we aggregated all of the scRNA-seq data into a single data matrix. This integrated data set combined the tumor, metaplastic, normal sites and PBMCs scRNA-Seq results across all samples and patients. To reduce experimental variance for this combined data set, we regressed out the batch effects from library preparation and variation in sequencing depth for all of the samples and also removed computationally detected doublets
(Methods, Supplementary Methods).
Overall, PCA clustering and UMAP analysis identified 40 distinct cellular clusters that were specific for a variety of cell types including epithelial, stromal (fibroblasts, endothelial cells), lymphocytes, macrophages and mast cells -these cell types were found among all of the patient tissue samples ( Supplementary Figures 1B and 1C, Figure 1E ). On closer examination, each cell type had multiple and distinct transcriptional states. For additional characterization of transcriptional states across all patients, we aggregated the data for each cell type across samples and conducted a clustering analysis (Methods).
Classifying tumor, normal and metaplastic epithelial cell populations
We detected differences between tumor, metaplastic and normal epithelial cells, differences in tumor epithelium derived from different patients as well as intra-tumoral sub-clonal heterogeneity within an individual tumor.
We identified epithelial cells which expressed PGC, TFF1, MUC5AC, EPCAM, GIF, CHGA ( Supplementary Figure 2A, 2B ) from our integrated dataset. On close inspection, we identified three subclasses of epithelial cells. The first subclass consisted of normal gastric epithelial cells -over 80% of these cells came from the normal gastric tissue samples ( Figure   2A , B, C). All samples had normal epithelial cells regardless of whether these cells originated from gastric tumor, normal or metaplasia tissue (Supplementary Figure 2C) .
The second subclass consisted of tumor-specific epithelial cells -with 98% of these cells originating from the gastric carcinoma samples. Interestingly, each cluster in this subclass were The third subclass involved epithelial cells which were tumor-like. This class contained approximately 50% of cells from a patient P6649 who had gastric metaplasia but did not have GC. Given their origin and histopathologic result, we classified these cells as representing metaplastic or dysplastic epithelial cells, which had a subset of transcriptional features that overlapped with the tumor epithelial cell sub-category.
As an independent determination of gastric tumor versus normal epithelial cells, we employed a completely different method that uses a supervised machine learning algorithm. Called scPred, this approach eliminates the statistical inconsistencies seen with other single cell methods and thus provides highly accurate cell type assignment (10). We applied scPred on gastric epithelial cells derived from normal and tumor tissue. Specifically, we randomly subset tumor and normal site derived cells into two. One subset from each of these classes was included in the training dataset to build the scPred prediction model. We tested this model on all of the remaining cells for all samples. When we compared the scPred results to our Seurat analysis, the results were concordant. For example, seventy-seven percent of cells in the tumor-like epithelium class were found to be distinct and not classified as normal gastric epithelial cells ( Figure 2D , Supplementary Figure 2D ). Thus, scPred confirmed the specific transcriptional differences among the normal, tumor and tumor-like epithelial subclasses.
Gene expression differences among the epithelial cell subclasses
Specific gene expression differences distinguished the three subclasses of epithelial cells. Our analysis of the normal gastric epithelium identified distinct mucosal cell populations such as pit cells, mucous neck cells, zymogen secreting chief cells, intrinsic factor producing parietal cells and neuroendocrine cells (Supplementary Figure 2B) . In contrast, tumor epithelium and tumor-like epithelium downregulated some of these gastric mucosa marker genes such as MUC6, TFF2, TFF1, MUC5AC ( Supplementary Table S5 ). Tumor epithelium had increased expression of intestinal mucosa markers TFF3, FABP1, SPINK4, MUC13 and REG4. Tumorlike epithelium had significantly increased expression of the previously identified gastric cancer marker genes KRT7 and KRT17 (11), SOX4 and HES1 that have been implicated in metaplasia pathogenesis (12). Compared to normal gastric cells, both tumor and tumor-like epithelial cells had upregulation of gene sets that included pathways for Myc, DNA repair and Notch signaling (Supplementary Figure 2E) . However, only tumor cells had higher upregulation of EMT and KRAS signaling compared to the other epithelial cell classes.
Copy number alterations distinguish tumor and normal epithelium
Using scRNA-seq, one can detect large copy number changes within individual cells (13).
Specifically, DNA copy number changes such as amplifications or deletions over extended segments of the genome (megabases involving chromosome arms) leads to a concomitant increase or decrease in expression for genes in that segment (Supplementary Methods). We determined which cells had these large copy number changes among our samples. Copy number changes were inferred according to the posterior probability for each cell to belong to one of the components with lower or higher gene expression indicative of deletion or amplification respectively. We excluded the sample from patient P6709 from this analysis since we only detected 21 epithelial cells from the tumor site, possibly indicative of response to neoadjuvant chemotherapy ( Supplementary Figures 2B, 1A , Supplementary table 4) .
To identify copy number alterations, we analyzed each patient's normal epithelial cells versus the matched tumor or tumor-like epithelial cells (Figure 2E, Supplementary Figure 3A) . A wide spectrum of chromosome arm imbalances were present in these tumors. For patient P6207, we detected genomic amplifications in chromosome arms 7p, 7q, 8q and 9q. Also, we identified a deletion in 10p. Patient P6342's tumor had amplification of 20q with deletion of 4q.
Patient P5846's tumor had an amplification of 19q. Patient P5866's tumor had deletion of 16q.
Patient P5931's tumor also had amplifications of 7p and 7q that have been previously described in gastric cancer (14) . For Patient P6649 with metaplasia and P6592, samples contained only a small number of cells with significant copy number changes. Overall, these results provide additional orthogonal confirmation of the distinction between normal and tumor epithelium.
Cancer cell differences across samples and tumor clonal heterogeneity
We analyzed tumor and tumor-like epithelial cells for the transcriptional activation of various oncogenic pathways (Supplementary Methods). We observed significant differences in activation levels across patients (ANOVA FDR p value < 0.05) indicating variation in cancer cells between patients ( Figure 2F ). Interestingly, these activation profiles did not cluster according to differences between the molecular subtypes of MSI and MSS.
The individual patient tumors contained multiple clusters of tumor or tumor-like cells, an indication of intra-tumoral sub-clonal heterogeneity. We conducted a pathway analysis to understand differences in signaling pathway activation across these subclones within a patient's tumor. Upon hierarchical clustering, pathway activation profiles grouped into three to five subpopulations for each patient's tumor confirming a sub-clonal structure ( Figure 2G,   Supplementary Figure 4 ). For example, heterogeneity in P6207 was characterized by differences in cell cycle, KRAS pathway, Wnt activation ( Figure 2G ). We postulate that these sub-populations may have a distinct growth advantage compared to other cells lacking these changes.
TME reprogramming leads to macrophage states other than M1 and M2 classification
TME macrophages had distinct cellular and gene expression changes compared to normal gastric tissue, some of which have not been described. This result is consistent with the observation that macrophages acquire heterogenous phenotypes depending on their activating stimulus (15). Macrophage phenotypes are called M1 or M2 with anti and pro-tumorigenic functions respectively. However, the gene expression signatures we observed did not fall in line with either the canonical M1 or M2 classes.
First, we detected various subclasses of myeloid lineage cells as seen with 11 distinct clusters detected as determined by marker genes (Figure 3A-D) . This was observed consistently across all patient samples (Supplementary Figure 5A) . The nine monocyte-macrophage clusters were defined by marker gene expression of CD14, FCGR3A, CD68. The two dendritic cell (DC) clusters were defined by marker gene expression of CLEC4C, ID2, IRF4, CD83 ( Figure 3C ). Notably, macrophages and DCs were significantly enriched in tumor compared to normal gastric tissue (z test of proportions, p < e-07) ( Figure 3E ).
We examined the expression of marker genes for M1 (e.g. CCL19, TNF, CCL5) and M2 (e.g. MRC1, CCL18, CCL13, CD163) states across the six macrophage clusters observed in gastric tissue (15) ( Figure 3F ). Expression of M1/M2 genes did not distinguish cell types as seen in different clusters. Moreover, these genes were co-expressed in the same cluster. This result suggests that the transcriptional heterogeneity was independent of the M1/M2 classification. We identified the differentially expressed genes (Bonferroni p < 0.05, log fold change > 0.25, genes expressed in >25% cells in a cluster) across all clusters to assess heterogeneous phenotypes ( Supplementary Table 6 ). This analysis revealed that heterogeneity in the six macrophage clusters was related to significant differences (Bonferroni adjusted p < 0.05) in the expression of HSP family genes, THBS1, chemokines including CCL20, CCL18, CCL3, matrix metalloproteinase genes, complement family genes and cell cycle regulation genes ( Figure   3G ). Clusters also showed significant differential enrichment (ANOVA, FDR p < 0.05) of Figure 3H ). Monocytes were present in a single trajectory state with few tissue macrophages. The majority of tissue macrophages differentiated along two distinct states. This results suggests that tumor infiltrating macrophages differentiate from monocytes but retain some fundamental similarities to macrophages within normal tissue.
DCs had two subclasses which demonstrated some unique transcriptional properties. One subclass had genes that define plasmacytoid DCs -these genes included IL3RA (CD123) and CLEC4C (CD303). This subclass was detected predominantly in PBMCs with only a limited number of this type of cell in the TME (Figure 3C, Figure 3D ). A second DC subclass was enriched in the TME and showed significant differential expression of activated DC gene markers CD83, CCR7, IL7R and ID2 (16) ( Supplementary Table S7 , Supplementary Figure   5C ) (17). This DC subclass expressed the chemokines CCL22, CCL17, CCL19 and IL32 which are associated with recruitment of naïve T cells. Moreover, this subclass had differential expression of IDO1 which is a gene marker for an immunosuppressive phenotype (18, 19) . This result represented a novel gene expression program in TME infiltrating DCs not previously described.
We compared activity levels of 1,558 experimentally derived immunologic gene signatures containing the term 'macrophage', 'DC' or 'monocyte' (Supplementary Methods, Supplementary Table S8 ) to these gene expression profiles. The identity of monocyte and DCs were confirmed using this approach. Also, these results provided the gene set information indicating the activation phenotype of tumor specific DCs. Each macrophage cluster was enriched for gene sets derived from a variety of experimental conditions. Hence, macrophage heterogeneity and variable states likely reflect stimulus-based context with the TME.
Regulatory genes controlling gene expression of a group of genes are referred to as regulons.
We identified regulons for these different transcriptional cell states using the analysis program SCENIC (5). This analysis identified transcriptional regulators such as IRF4 in DCs and also revealed a distinct set of regulatory genes defining the various macrophage populations including NFKB1, ETS2, CREM, REL, STAT1, FOXO3, etc. ( Supplementary Table S9 ). Our data provides direct in vivo evidence that tumor-specific macrophages exist in a continuum of stimulus-dependent functional states regulated by a specific set of genes rather than the M1/M2 paradigm. We also discovered a TME-specific gene expression program in DCs.
TME exhausted T cells have high CXCL13 expression and proliferation
Exhausted T cells were a prominent feature of the gastric TME compared to normal tissue. TME was also significantly enriched for Treg cells compared to normal. Initially, we identified CD4 helper T, CD8 T, NK, Treg, plasma and B cells using classic immunophenotyping markers. We Figure 7A) . We examined each cluster for the dominant sample origin (normal, tumor or PBMC), expression of naïve markers (CCR7, SELL), tissue effector memory markers (CD69, ITGAE, ITGA1) and cytotoxic genes (GZMB, GZMA, PRF1, IFNG, NKG7) ( Figure 4A,B) . CTL subclasses included naïve tumor CTLs (cluster 0), effector normal CTLs (cluster 1), effector PBMC CTLs (cluster 19) and two subclasses of tumor effector CTLs (clusters 6, 22). Analysis of differential gene expression identified distinct signatures among the CTL subclasses ( Supplementary Table S10 ). Immune checkpoint or costimulatory molecule gene expression was not significantly different between the two sub-classes. The second subclass (cluster 6) had lower exhaustion and proliferation plus significantly higher expression of CXCL13 as previously identified in tumor but not in viral TEx (Supplementary Figure 7C ) (26). Also, these cells expressed high RBPJ, NR3C1 and BATF that are regulators of CD8 T cell fate (27). Our results thus demonstrated that effector CTLs in the TME are exhausted unlike normal tissue or PBMCs with two distinct subclasses characterized by high CXCL13 expression or proliferation.
Within cancers one observes exhausted T cells (TEx
To verify our findings, we conducted multiplex immunofluorescence staining for pan-
cytokeratin/SOX-10 (expressed in epithelial cells), CD45RO (memory T cells), CD3 (T cells) and
PD-1 (exhausted T cells) in tumors from four patients where adequate tissue samples were available ( Figure 4D, Supplementary Figure 8A) . We detected these cell lineages in all samples including cellular sub-populations of effector T cells (CD45RO, CD3 positive) and exhausted effector T cells (PD-1, CD45RO, CD3 positive) based on co-expression analysis (Supplementary Figure 8B) . The stromal cells and macrophages were also apparent as they lacked expression of these markers.
Increased Tregs in the gastric TME contribute to immunosuppression
Tregs were significantly enriched in the gastric TME compared to normal gastric tissue, thus indicating an important mode of immunosuppression ( Supplementary Figure 9A Figure 9E) . These cells are likely to represent follicular helper-like CXCL13 producing CD4 cells that are associated with tertiary lymphoid structures (28,29).
NK cells with three subclasses were detected in PBMCs (cluster 2) and both tumor and normal tissue (clusters 13, 14) (Supplementary Figure 10A) . These cells contained a mix of rare Figure   10B ) (30) . Cells in tumor and normal sites clustered together indicating transcriptional similarity.
populations of invariant NK cells, innate lymphoid cells and NK cells (Supplementary
These cells in the tumor expressed cytotoxic molecules such as GZMA, XCL2, CCL5, PRF1, CCL3, CCL4 indicating a potential role in mediating an anti-tumor immune response (Supplementary Figure 10C) . Cells also expressed several inhibitory and co-stimulatory molecules including TNFRSF18 (GITR), CD96 and KIR2DL4 expression representing targets for modulating their function.
B Cells from gastric TME and normal sites clustered together indicating transcriptional similarity among these cells (Supplementary Figure 10D) . However, plasma cell clusters showed significant differences in the expression of genes encoding immunoglobulin isotypes when comparing gastric TME versus normal tissue (Supplementary Figure 10E, F) . Specifically, plasma cells in normal tissue expressed genes encoding for IgA, those in tumor were enriched for IgG (Bonferroni p < 0.05, logFC > 0.2, expressed in >25% cells).
Identification of jointly regulated genes of lymphocyte cell states
Our clustering analysis successfully revealed lymphocyte sub-populations driven by lineage as well as subclasses of their transcriptional cell states. Regulatory genes control group of genes with their activation or suppression, occurring as a joint unit. These regulatory genes are referred to as regulons. We identified these regulons using the analysis program SCENIC (5) ( Supplementary Table S11 ). In CXCL13-high tumor-TEx cells we detected significant enrichment of FOXO1 activity (ANOVA FDR p < 0.05) that is required for post antigen expansion of CD8 T cells (31). In high CXCL13-CD4 T cells, BATF activity was prominent validating their similarity to recently described CXCL13 producing helper T cells (32). We successfully identified FOXP3 and BATF gene network enrichment in Tregs confirming the accuracy of this approach. We discovered additional transcriptional regulators of Treg fate in the TME including KDM5B, MAF, IKZF2, SOX4, BCL3, etc. These regulons are of potential translational value given the interest in targeting epigenetics for modulating immune cell states for immunotherapy (33).
TME reprogramming of the fibroblasts, pericytes and endothelial stroma
We discovered a transcriptional reprogramming of stromal cells in the tumor compared to normal tissue that allows the generation of a tumor-specific extracellular matrix (ECM). Our Importantly, all three cell types were enriched in tumor tissue compared to normal ( Figure   5B ,5D). Stromal cells are responsible for the production and maintenance of ECM that provides mechanical support to cells and also influences their growth by interactions. Hence, these differences in number can impact the characteristics of ECM in tumor compared to normal tissue.
Genes encoding for components or regulators of the ECM have previously been identified as the 'matrisome' (35, 36) . It consists of core factors such as collagens, proteoglycans and ECM glycoproteins that make up the ECM as well as an associated program that consists of ECM regulators, secretory factors and ECM-affiliated proteins. To understand the phenotypical differences in stromal cells found in normal or tumor tissue, we compared their significantly differentially expressed genes (Bonferroni adjusted p < 0.05, logFC > 0.25 and expressed in > 25% cells) to the matrisome gene expression program. Tumor-specific fibroblasts, pericytes and endothelial cells expressed diverse ECM components, including glycoproteins, collagens and proteoglycans, as well as ECM regulators, affiliated proteins and secretory factors as compared to normal stromal cells ( Figure 5E , Supplementary Table S12 ). Additionally, fibroblasts in tumors had significant overexpression of ACTA2 compared to normal tissue, indicative of their contractile ability (Supplementary Figure 11D) .
Stromal cells at tumor or normal sites had significantly different regulatory genes or regulons (ANOVA FDR < 0.05) ( Supplementary Table S13 ). For example, tumor-specific endothelial cells had greater activity of SOX18 and SOX7 which are known regulators of a variety of endothelial cell processes (37). Tumor-specific fibroblasts had high activity of EGR2 that can influence fibrosis (38). Tumor-specific pericytes were enriched for FOXF2 activity that is known to regulate pericyte differentiation (39). Hence, our approach distinguished differences in both the gene expression program and its regulators between tumor and normal stromal cells.
TME specific cellular communication has the potential to influence cell states
We discovered a TME-specific intercellular communications network that can potentially affect cellular behavior. First, we identified receptor-ligand interactions between different cell types using CellPhoneDB, which infers statistically significant interactions from a comprehensive data catalogue. We then compared these networks between tumor and normal tissue to generate an interactome specific to the TME, which was not present at significant levels in normal tissue ( Figure 6A , Supplementary Table 14 ).
Stromal cells were among the most prolific interactors. Prominent communication between epithelial cells, fibroblasts, pericytes and endothelial cells occurred through various integrin
receptor interactions with collagen, fibronectin and THBS1 ligands ( Figure 6B ). We also detected bidirectional interactions between ephrin receptor family and ephrin ligands in epithelial and endothelial cells that can influence cell phenotypes (40). Among growth factor signaling that can promote proliferation and survival of cancer cells, we could detect expression of EGFR and MET receptors on epithelial cells together with respective ligand expression on stromal cells. We also detected significant EGFR signaling interactions in fibroblasts.
Fibroblasts were a prominent source of Wnt ligands with expression of corresponding receptors on tumor epithelial cells, endothelial cells, fibroblasts and pericytes. This included a LGR4 -RSPO3 interaction that has the potential to regulate stemness (41) ( Figure 6C ), validating our previous discovery of fibroblast derived RSPO3 in an organoid model of gastric cancer (42).
Autocrine Notch signaling was evident in endothelial cells, a known regulator of angiogenesis (43), together with paracrine support from tumor epithelium and fibroblasts. Interactions promoting Notch signaling, which can regulate their transition to myofibroblasts (44), were also significant in fibroblasts ( Figure 6D ). Angiogenic receptors KDR, FLT1, FLT4, PDGFB, TEK on endothelial cells and pericytes had significant autocrine and paracrine interactions with their respective ligands ( Figure 6E ). Among the interactome were 19 cytokines including chemokines, interleukins, tumor necrosis factors (TNFs) and their corresponding receptors that can influence immune cell fates.
DISCUSSION
We leveraged paired distal normal tissue and PBMCs in our study to analyze the cellular dysregulation and biological changes in the GC TME. With single cell gene expression analysis, we demonstrated that GC TME leads to a series of dramatic cellular changes compared to matched normal stomach mucosa. Specifically, we noted increases in cell numbers of fibroblasts, endothelial cells, pericytes and Tregs in the TME. We also identified transcriptional cell states unique to the TME. This included two subclasses of exhausted CTLs unique to the TME characterized by CXCL13 expression or increased proliferation and TMEspecific DCs. We also generated gene expression profiles for tumor associated macrophages that consisted of six heterogenous subclasses not confined to a binary M1/M2 classification.
We demonstrated that stromal cells in the TME have a gene expression program not found in normal tissue that encodes for a specific extracellular matrix composition. These results identified novel gene regulatory networks and intercellular communication networks across these TME specific cell types and states.
We validated previously described changes in normal, metaplastic and tumor epithelial cells (12,45) and were additionally able to elucidate intra-tumor heterogeneity by examining the activity of various cancer promoting mechanisms within the tumor cells. The diversity in activation profiles suggests that targeting multiple clones with different combination strategies may be necessary to eradicate them completely.
Immunosuppression in GC TME was evident by the increased proportion of Tregs compared to normal tissue. We identified several checkpoint and costimulatory molecules on these cells, and their transcriptional regulators. These regulators can be investigated to understand Treg biology and to derive therapeutic targets. Indeed, recent evidence indicates that anti-CTLA4 activity is a consequence of Treg depletion in the TME (46). We detected expression of multiple immune checkpoints on cytotoxic T cells similar to other studies (22,47). These checkpoints were also detected on helper T and Treg subsets. Thus, it is important to understand the effects of immune checkpoint blockade on distinct T cell subpopulations that express the same target. Our analysis reveals molecules and transcriptional regulators responsible for these states. Plasma cells in tumor tissue expressed IgGs rather than IgAs that were detected in paired normal tissue. IgGs have been associated with a pro-cancer role by influencing myeloid cell Fc-receptors (48).
We demonstrated that tumor immune cells are transcriptionally closer to normal tissue counterparts than PBMCs. Our trajectory analysis shows that the majority of tissue macrophages are distinct from monocytes, supporting their different origins (49). Application of reference profiles derived from PBMCs to tumor infiltrating immune cells should also be interpreted with caution.
Interactome analysis demonstrated pro-tumor effects of TME components and also the influence of cancer cells on the TME. Tumor-specific interactome represents potential treatment targets to inhibit cancer proliferation, overcome the immunosuppressive microenvironment and restore the cancer immunity cycle. Additionally, while some targets such as Wnt inhibition have previously been regarded only in the context of tumor epithelial cells, our analysis demonstrates that this might have implications for the TME.
Our study did not consider spatial context and might be affected by the dissociation process.
For immune cells in particular, the use of dual single-cell proteomics and transcriptomics is likely to provide a more refined analysis of immune cell sub-types (50).
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Villani amp_1p  amp_1q  del_2p  amp_2q  amp_3p  amp_3q  del_4p  amp_4q  del_5p  del_5q  del_6p  amp_6q  amp_7p  amp_7q  del_8p  amp_8q  del_9p  amp_9q  del_10p  amp_10q  amp_11p  del_11q  del_12p  amp_12q  amp_13q  del_14q  del_15q  amp_16p  del_16q  amp_17p  del_17q  amp_18p  del_18q  amp_19p  del_19q  amp_20p  amp_20q  del_21q 3  4  5  12  FCER2  CD14  CXCR1  CCR2  CCL22  CCL17  IL10  CD163  CCL13  CCL18  CCL23  MRC1  MS4A4A  CD36  MS4A6A  BIRC3  FAS  BCL2A1  CCL15  CCL5  TNF  CXCL9  CXCL10  CCL19  CXCL11  IL7R  IL15RA  IL2RA 0  2  3  4  5  12  HMGN2  H2AFZ  HIST1H4C  STMN1  TOP2A  SLC40A1  SELENOP  C1QA  C1QB  C1QC  CXCL1  CCL3  CCL3L1  INHBA  G0S2  SPP1  MMP9  APOE  MMP12  CCL18  CCL20  TIMP1  SERPINB2  S100A8  THBS1  HSPB1  HSPA1B  HSPA6  IGKC  IGLC2   − 19  22  TNFRSF4  CD226  CD40  TNFRSF9  CD27  TNFRSF18  ICOS  VSIR  CTLA4  LAG3  HAVCR2  CD96  TIGIT  PDCD1  NKG7  IFNG  PRF1  GZMB  GZMA  ITGA1  ITGAE  CD69  SELL  CCR7  CD8B 
Legends to figures and tables
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